You just read:

Theravance Biopharma Announces Positive Results Including Biomarker Data from Phase 1 Multiple-Ascending Dose Study of TD-0714, an Inhibitor of Neprilysin (NEP)

News provided by

Theravance Biopharma, Inc.

25 Oct, 2016, 08:30 ET